Opt-in Fee. If CureVac exercises its option to Opt-In under Section 7.1 above, CureVac shall pay Genmab a non-refundable and non-creditable Opt-In fee of Three Million Dollars (US$ 3,000,000) within [*****] after CureVac’s receipt of an invoice of the respective amount from Genmab; and no Option Exercise Fee shall be payable by Genmab for the respective Optioned Target. If the Option Exercise Fee has already been paid, CureVac shall reimburse such payment to Genmab within [*****] of receipt of invoice.
Opt-in Fee. Upon the Effective Date of GSK's Exercise of its Opt-In Right with respect to any Discovery Program, it shall simultaneously pay to Theravance a non-refundable fee in partial consideration for the acquisition of license rights under the Theravance Patents and the Theravance Know-How by GSK under this Agreement, as follows:
(i) for a Discovery Program in which the lead Theravance Compound [*] as of the Initial Due Diligence Commencement Date: [*]; [*]=CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.
(ii) for a Discovery Program in which the lead Theravance Compound [*] as of the Initial Due Diligence Commencement Date: [*]; and
(iii) for a Discovery Program in which the lead Theravance Compound [*] as of the Initial Due Diligence Commencement Date: [*]. provided always that, in recognition of the increased value of the licences granted hereunder as a result of the work performed by Theravance in the Interim Period, [*].
Opt-in Fee. The opt-in fee under Section 2.6(c)(i) above, to be determined by Genentech [CONFIDENTIAL TREATMENT REQUESTED], shall be [CONFIDENTIAL TREATMENT REQUESTED] cost of such product attributable to rights in the United States. [CONFIDENTIAL TREATMENT REQUESTED]. The Parties shall seek to agree on the amount of such opt-in fee, and to the extent the Parties are unable to agree within a twenty (20) day period, such dispute shall be subject to Section 17.2.
Opt-in Fee. Lilly shall pay a fee of US$ ten (10) million to Immunocore within [***] of the date of exercise of each Lilly Co-Development Option.
Opt-in Fee. The opt-in fee under Section 2.6(b)(i) above, to be determined by Genentech [*] shall be based on the terms of the agreement with such Third Party attributable to rights in the United States, and shall be intended to compensate Genentech for [*] of Genentech’s costs in acquiring the rights in the United States to such product under such agreement with such Third Party [*]. The Parties shall seek to agree on the amount of such opt-in fee, and to the extent the Parties are unable to agree within a twenty (20) day period, such dispute shall be subject to Section 17.2.
Opt-in Fee. The opt-in fee under Section 2.6(c)(i) above, to be determined by Genentech [*] shall be [*] cost of such product attributable to rights in the United States[*]. The Parties shall seek to agree on the amount of such opt-in fee, and to the extent the Parties are unable to agree within a twenty (20) day period, such dispute shall be subject to Section 17.2.
Opt-in Fee. The Opt-In Fee shall be equal to a multiple of the Opted-Out Party’s Share of the Development Costs incurred by the Party that continued Development after the opt-out and prior to the effective date of the Opted-Out Party’s election to opt back in, in accordance with Section 3.7(b), selected from the following table based on the time that the opt-out became effective (i.e., the end of the notice period for opting out): Preclinical Development [*] After Preclinical Development but before Commencement of Phase 2 Trials [*] After Commencement of Phase 2 Trials but before Commencement of Phase 3 Trials [*] After Commencement of Phase 3 Trials [*]
Opt-in Fee. Upon the Effective Date of GSK's Exercise of its Opt-In Right with respect to any Discovery Program, it shall simultaneously pay to Theravance a non-refundable fee in partial consideration for the acquisition of license rights under the Theravance Patents and the Theravance Know-How by GSK under this Agreement, as follows:
(i) for a Discovery Program in which the lead Theravance Compound [*] as of the Initial Due Diligence Commencement Date: [*];
(ii) for a Discovery Program in which the lead Theravance Compound [*] as of the Initial Due Diligence Commencement Date: [*]; and
(iii) for a Discovery Program in which the lead Theravance Compound [*] as of the Initial Due Diligence Commencement Date: [*]. provided always that, in recognition of the increased value of the licences granted hereunder as a result of the work performed by Theravance in the Interim Period, [*].
Opt-in Fee. In addition, Match will pay to Yahoo ** for each Opt-In User ** as measured on a cumulative basis during the Term (the "Opt-In Threshold"). Notwithstanding the foregoing, in no event will the total amount that Match pays to Yahoo in connection with the Agreement exceed **. After the Opt-In Threshold has been reached, Match's payments to Yahoo for Opt-In Users in excess of the Opt-In Threshold will be due and payable within thirty (30) days of the end of each month based on the number of Opt-In Users during that month. With each payment, Match will provide Yahoo a report certified by an officer of Match showing the number of Opt-In Users. Match will maintain complete and accurate records in accordance with generally accepted methods of accounting to revenue share transactions described in this section, and will allow Yahoo, at its own expense, to direct an independent certified public accounting firm or other qualified independent auditor to inspect and audit such records during normal business hours with written notice to Match to determine whether there has been any underpayment of payments herein. In the event that any audit reveals ail underpayment of more than **, Match will pay the reasonable cost of such audit and the amount equal to such underpayment.
Opt-in Fee
